Year: 2025

TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (TSXV:MATA, OTCQB:MATAF, FSE:IU3) (“Matador” or the “Company”), the Bitcoin Ecosystem Company, is pleased to announce that it has closed the first tranche (the “Initial Closing“) of its previously announced secured convertible note facility (the “Facility”) with ATW Partners (the “Investor”) pursuant to which it has issued convertible notes (“Notes“) in the aggregate principal amount of USD$10,500,000. The Facility will be used exclusively to purchase Bitcoin for Matador’s balance sheet. An additional USD$89.5 million remains available under the Facility in follow-on drawdowns, subject to the receipt of all regulatory approvals and other specified conditions. This capital supports Matador’s long-term BTC plan, including:Acquiring up to...

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients expected at ESMO Asia 2025 Strong financial position with approximately $408 million in cash, cash equivalents, and investments as of September 30, 2025 BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX) today announced financial results for the third quarter ended September 30, 2025 and provided a business update. “The FDA’s recent Breakthrough Therapy Designation for ficerafusp alfa in first-line HPV-negative HNSCC represents an important milestone for Bicara and validates the strength of our clinical data and our development...

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trial LYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killing Lyell management will host an investor webcast at 8:30 AM ET todaySOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has strengthened its solid tumor pipeline by acquiring global rights to LYL273 (formerly GCC19CART), a novel autologous...

Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization. Patient enrollment in SYMON-II clinical trial now approximately 50% completed. Recent private placement transaction completed in October 2025; Company continues to explore further financing opportunities.ACTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient testing solutions for critical care, announced financial results for the quarter ended September 30, 2025, and highlighted continued progress across its clinical, operational, and financial initiatives. Third Quarter 2025 and Recent Corporate HighlightsSYMON-II Pivotal Clinical Study Continues:...

Q3 2025 Select HighlightsSales Increased 29% to $19.0 Million Gross Profit Rose to $7.2 Million; Gross Margin Improved to 38% Net Loss Narrowed to $0.4 Million Adjusted EBITDA Improved to $898,000 Unrestricted Cash Rose to $5.4 Million – Highest Level Since 2022   Total Debt Declined 59% from December 31, 2024RONKONKOMA, N.Y., Nov. 10, 2025 (GLOBE NEWSWIRE) — SUNation Energy, Inc. (Nasdaq: SUNE) (the “Company”), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced financial results for the third quarter ended September 30, 2025 (“Q3 2025”) and reiterated full year financial guidance for total sales and Adjusted EBITDA. “Our third quarter results reflected increased residential demand for solar and battery storage due to...

Delivered 42% revenue growth year-over-year Strong gross margins of 15.1%, expansion of 80 basis points Reaffirming Adjusted EBITDA guidance for full year CHICAGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 HighlightsRevenues of $160.5 million, compared to $113.3 million in the third quarter of 2024, with railcar deliveries of 1,304 units compared to 961 units in the prior year period Gross margin of 15.1% with gross profit of $24.2 million, compared to gross margin of 14.3% with gross profit of $16.2 million in the third quarter of 2024 Recorded a $17.6 million non-cash adjustment...

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women’s health are encouraged to attend, either In-person or virtually LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today is presenting an update on recent progress with its IMNN-001 development program for the treatment of newly diagnosed advanced ovarian cancer, including a review of positive data from the Company’s Phase 2 OVATION 2 Study and the minimal residual disease (MRD) study conducted in partnership with Break Through Cancer....

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models  Activin E reduction in lowest single dose cohort of INLIGHT was sustained through six months, supporting once or twice a year dosing Achieved key AATD treatment goals to recapitulate the MZ phenotype with WVE-006, GalNAc-RNA editing oligonucleotide, in RestorAATion-2 trial: AAT protein exceeded 20 µM during an acute phase response, basal AAT levels reached 13 µM, wild-type M-AAT protein reached 64% of serum AAT, Z-AAT was reduced by 60% WVE-N531 in DMD and WVE-003 in HD remain on track Cash and cash equivalents of $196.2...

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers  SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in three Late Breaking Science sessions at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions 2025 in New Orleans, LA. Two of the presentations were simultaneously published in the Journal of the American College of Cardiology.1,2 “These additional analyses from MAPLE-HCM expand on the primary finding that aficamten is superior to metoprolol on...

Achieves Year-Over-Year Growth in Sales, Adjusted Operating Income and Adjusted EPS SPRINGDALE, Ark., Nov. 10, 2025 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:(in millions, except per share data) Fourth Quarter   Twelve Months Ended    2025     2024     2025     2024Sales $ 13,860   $ 13,565   $ 54,441   $ 53,309               Operating Income $ 158   $ 525   $ 1,098   $ 1,409Adjusted1Operating Income (non-GAAP) $ 608   $ 512   $ 2,287   $ 1,820               Net Income Per Share Attributable to Tyson $ 0.13   $ 1.00   $ 1.33   $ 2.25Adjusted1Net Income Per Share Attributable to...